药明生物韩杨网络研讨会：从开发到确认的稳健C1q结合检测方法
From Development to Qualification: A Robust C1q-Binding Assay
药明生物分析开发副总监韩杨将在网络研讨会介绍基于生物层干涉（BLI）的抗体-C1q结合检测方法的开发与确认，以曲妥珠单抗为模型IgG1，使用Octet® BLI平台定量结合亲和力。会议将展示特异性、精密度、准确度、线性和稳健性等关键确认指标结果，说明该方法适用于治疗性抗体开发并与ICH指南保持一致。
Still analyzing C1q binding the hard way? Consider a novel biosensor-based approach for robust, reproducible results.
Register Free: https://www.biopharminternational.com/bp_w/C1q-Binding-Assay
Event Overview:
C1q protein binding to therapeutic antibodies can trigger the complement cascade and lead to targeted destruction of cancer cells by complement dependent cytotoxicity (CDC). Quantifying the interaction between a therapeutic antibody and C1q can give an indication of its CDC activity.
In this webinar Han Yang from WuXi Biologics, will discuss the development and qualification of a biolayer interferometry (BLI)-based method for assessing antibody-C1q binding. Using trastuzumab as a model IgG1, the webinar will cover key considerations for developing a reliable C1q-binding assay and how the Octet® BLI platform can be used to quantify binding affinity. Results across key qualification criteria, including specificity, precision, accuracy, linearity, and robustness, will be presented, demonstrating the suitability of the method for therapeutic antibody development and alignment with ICH guidelines.
Key Learning Objectives:
- Discuss how BLI enables rapid, label-free antibody-C1q interaction analysis
- Learn the fundamentals of assay design, orientation, and biosensor selection
- Explore assay performance across a range of key qualification parameters
Who Should Attend:
- Researchers working in analytical development
- Scientists working in biologic manufacturing and quality control
Speaker:
Han Yang, M.S.
Associate Director, Analytical Development
WuXi Biologics
Han Yang is an Associate Director in Analytical Development at WuXi Biologics, supporting biologics from discovery through CMC development and commercialization. She specializes in large-molecule analytics, biosensor characterization, biophysical analysis, and analytical strategies for therapeutic proteins and antibodies. Previously at Pfizer, she applied biosensor platforms to drive decision-making in drug discovery and candidate optimization.
Register Free: https://www.biopharminternational.com/bp_w/C1q-Binding-Assay
来源：BioPharm International · biopharminternational.com